Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- Studies evaluating switches in suppressed patients receiving stable lopinavir/ritonavir-based antiretroviral therapy switched to raltegravir found improvements in serum lipids
- SWITCHMRK studies[Eron 2010] were stopped at Week 24 because of increased risk of virologic failure; however, the SPIRAL study[Martínez 2010] did not demonstrate such a difference
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content